Journal of Endocrinological Investigation

, Volume 23, Issue 7, pp 457–462 | Cite as

Does kidney transplantation normalise cortisol metabolism in apparent mineralocorticoid excess syndrome?

  • M. Palermo
  • G. Delitala
  • G. Sorba
  • M. Cossu
  • R. Satta
  • R. Tedde
  • A. Pala
  • Cedric H. L. Shackleton
Original Article

Abstract

The syndrome of apparent mineralocorticoid syndrome (AME) results from defective 11β-hydroxysteroid dehydrogenase 2 (11β-HSD2). This enzyme is co-expressed with the mineralocorticoid receptor (MR) in the kidney and converts cortisol to its inactive metabolite cortisone. Its deficiency allows the unmetabolized cortisol to bind to the MR inducing sodium retention, suppression of PRA and hypertension. Thus, the syndrome is a disorder of the kidney. We present here the first patient affected by AME cured by kidney transplantation. Formerly, she was considered to have a mild form of the syndrome (Type II), but progressively she developed renal failure which required dialysis and subsequent kidney transplantation. To test the ability of the transplanted kidney to normalise the patient’s cortisol metabolism, we gave, in two different experiments, 25 and 50 mg/day of cortisone acetate or 15 and 30 mg/day of cortisol after inhibition of the endogenous cortisol by synthetic glucocorticoid (methylprednisolone and dexamethasone). The AME diagnostic urinary steroid ratios tetrahydrocortisol+5αtetrahydrocortisol/tetrahydrocortisone and cortisol/cortisone were measured by gas chromatography/mass spectrometry. Transplantation resulted in lowering blood pressure and in normalization of serum K and PRA. After administration of a physiological dose of cortisol (15 mg/day), the urinary free cortisol/cortisone ratio was corrected (in contrast to the A-ring reduced metabolites ratio), confirming that the new kidney had functional 11β-HSD2. This ratio was abnormally high when the supra-physiological dose of cortisol 30 mg/day was given. After cortisone administration, the tetrahydrocortisol+5αtetrahydrocortisol/tetrahydrocortisone ratio resulted normalised with both physiological and supra-physiological doses, confirming that the hepatic reductase activity is not affected. As expected, the urinary free cortisol/cortisone ratio was normal with physiological, but increased after supra-physiological doses of cortisone. The described case indicates a normalisation of cortisol metabolism after kidney transplantation in AME patient and confirms the supposed pathophysiology of the syndrome. Moreover, it suggests a new therapeutic strategy in particularly vulnerable cohorts of patients inadequately responsive to drug therapy or with kidney failure.

Key-words

Apparent mineralocorticoid excess syndrome AME syndrome 11βHSD deficiency low renin hypertension cortisol metabolism kidney transplantation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Stewart P.M., Krozowsky, Z.S. 11-Hydroxysteroid dehydrogenase. Vitam. Horm. 1999, 57: 249–324.PubMedCrossRefGoogle Scholar
  2. 2.
    Shimojo M., Stewart P.M. Apparent mineralocorticoid excess syndrome. J. Endocrinol. Invest. 1995, 18: 518–532.PubMedGoogle Scholar
  3. 3.
    White P.C., Mune T., Agarwal A.K. 11β-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr. Rev. 1997, 18: 135–156.PubMedGoogle Scholar
  4. 4.
    Edwards C.R., Stewart P.M., Burt D., Brett L., McIntyre M.A., Sutanto W.S., De Kloet E.R., Monder C. Localisation of 11β-hydroxysteroid dehydrogenasetissue specific protector of the mineralocorticoid receptor. Lancet 1988, 2: 986–989.PubMedCrossRefGoogle Scholar
  5. 5.
    Palermo M., Cossu M., Shackleton C.H.L. Cure of apparent mineralocorticoid excess by kidney transplantation. N. Engl. J. Med. 1998, 339: 1787–1788.PubMedCrossRefGoogle Scholar
  6. 6.
    Ulick S., Chan C.K., Rao K.N., Edassery J., Mantero F. A new form of the syndrome of apparent mineralocorticoid excess. J. Steroid Biochem. 1989, 32: 209–212.PubMedCrossRefGoogle Scholar
  7. 7.
    Mantero F., Palermo M., Petrelli M.D., Tedde R., Stewart P.M., Shackleton C.H.L. Apparent mineralocorticoid excess: Type I and type II. Steroids 1996, 61: 193–196.PubMedCrossRefGoogle Scholar
  8. 8.
    Li A., Tedde R., Krozowsky Z.S., et al. Molecular basis for hypertension in the “type II variant” of apparent mineralocorticoid excess. Am. J. Hum. Genet. 1998, 63: 370–379.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Mittal R., Agarwal S.K., Dash S.C., et al. Treatment of acute rejection in live related renal allograft recipients: a comparison of three different protocols. Nephron. 1997, 77: 186–189.PubMedCrossRefGoogle Scholar
  10. 10.
    Shackleton C.H.L. Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research. J. Steroid Biochem. 1993, 45: 127–140.CrossRefGoogle Scholar
  11. 11.
    Palermo M., Gomez-Sanchez C., Roitman E., Shackleton C.H.L. Quantitation of cortisol and related 3-oxo-4-ene steroids in urine using gas chromatography/mass spectrometry with stable isotope-labeled internal standards. Steroids 1996, 61: 583–589.PubMedCrossRefGoogle Scholar
  12. 12.
    Shackleton C.H.L., Stewart P.M. The hypertension of apparent mineralocorticoid excess (AME) syndrome. In: Biglieri E.G., Melby J.C. (Eds.), Endocrine Hypertension. Raven Press, New York, 1990, p. 155.Google Scholar
  13. 13.
    Wood V.J.H., Galligan J.P., Cannell G.R., Bochner F., Mortimer R.H. Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. Br. J. Clin. Pharmacol. 1984, 17: 55–59.CrossRefGoogle Scholar
  14. 14.
    Palermo M., Shackleton C.H.L., Mantero F., Stewart P.M. Urinary free cortisone and the assessment of 11β-hydroxysteroid dehydrogenase activity in man. Clin. Endocrinol. 1996, 45: 605–611.CrossRefGoogle Scholar
  15. 15.
    Stewart P.M., Walker B.R., Holder G., O’Halloran D., Shackleton C.H.L. 11β-Hydroxysteroid dehydrogenase activity in Cushing’s syndrome: Explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J. Clin. Endocrinol. Metab. 1996, 80: 3617–3620.Google Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2000

Authors and Affiliations

  • M. Palermo
    • 1
  • G. Delitala
    • 1
  • G. Sorba
    • 3
  • M. Cossu
    • 3
  • R. Satta
    • 3
  • R. Tedde
    • 2
  • A. Pala
    • 2
  • Cedric H. L. Shackleton
    • 3
  1. 1.Institute of EndocrinologyUniversity of SassariSassariItaly
  2. 2.Institute of Clinica MedicaUniversity of SassariSassariItaly
  3. 3.Department of Nephrology and DialysisSS. Annunziata HospitalSassariItaly

Personalised recommendations